Pharmacoeconomic evaluations of antifungal therapies

Area of Science:

• Infectious Diseases
• Pharmacoeconomics
• Healthcare Management

Background:

• Invasive fungal infections (IFIs) are a significant cause of illness and death in the U.S.
• IFIs lead to extended hospital stays and increased healthcare expenditures.
• While new antifungal treatments exist, their economic benefits are not well-established.

Purpose of the Study:

• To assess the pharmacoeconomic value of newer antifungal treatments, specifically echinocandins.
• To highlight the need for rigorous pharmacoeconomic studies in the field of invasive fungal infections.
• To identify all relevant costs associated with antifungal treatment, including drug acquisition and management of side effects.

Main Methods:

• Review of existing literature on pharmacoeconomic studies of invasive fungal infections.
• Analysis of cost components beyond drug acquisition, such as treatment efficacy and adverse events.
• Consideration of administrative costs related to formulary changes and clinician education.

Main Results:

• There is a scarcity of rigorous pharmacoeconomic data for newer antifungal agents like echinocandins.
• Effective pharmacoeconomic analysis must incorporate costs of treatment failure and drug side effects.
• Implementing new medications may incur additional administrative costs for clinician retraining.

Conclusions:

• More comprehensive pharmacoeconomic research is crucial for evaluating newer antifungal therapies.
• A holistic approach to cost analysis is necessary to understand the true economic impact of IFIs and their treatments.
• Informed formulary decisions require robust data on both clinical efficacy and economic value.